Myostatin inhibition in concert with perhaps other anti-TGF-β ligand therapies, and/or current anabolic and bisphosphonate therapies, may more significantly impact postnatal musculoskeletal properties of OI. This evidence concerns the gene TGFB1 and osteogenesis imperfecta.